



Universiteit
Leiden
The Netherlands

HIV and *Schistosoma* spp. interactions: epidemiology and consequences for detection and prevention in the lake region of Tanzania

Colombe, S.

Citation

Colombe, S. (2020, January 7). *HIV and Schistosoma spp. interactions: epidemiology and consequences for detection and prevention in the lake region of Tanzania*. Retrieved from <https://hdl.handle.net/1887/82478>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/82478>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/82478> holds various files of this Leiden University dissertation.

Author: Colombe, S.

Title: HIV and Schistosoma spp. interactions: epidemiology and consequences for detection and prevention in the lake region of Tanzania

Issue Date: 2020-01-07

CHAPTER 7 – SUMMARIZING DISCUSSION

I. INITIAL COMPREHENSION ON <i>SCHISTOSOMA</i> SPP. AND HIV INTERACTIONS	120
II. REVISITING THE CONCEPTUAL FRAMEWORK: WHAT GAPS DID WE FILL?	122
<i>1) Effects of Schistosoma spp. infection on HIV susceptibility and disease</i>	122
<u>A. Schistosoma spp. infection at time of HIV infection slows down AIDS progression</u>	122
<u>B. Schistosoma spp. co-infection increases HIV transmission</u>	123
<u>C. Schistosoma spp. co-infection decreases HIV RNA viral load</u>	123
<i>2) Effect of HIV on Schistosoma spp. infection</i>	126
<u>A. HIV co-infection reduces Schistosoma spp. egg excretion in men</u>	126
III. IMPLICATIONS FOR DIAGNOSIS AND PREVENTION	128
<i>1) Diagnosis of Schistosoma spp.: microscopy testing is not recommended for women and HIV-infected individuals</i>	128
<i>2) HIV prevention: targeting individuals present in Schistosoma spp.-endemic areas to contain the HIV epidemic</i>	128
IV. REMAINING QUESTIONS AND METHODOLOGY IMPROVEMENTS	130
<i>1) More longitudinal studies are needed</i>	130
<i>2) The immunological processes at stake are still not fully understood</i>	130
<i>3) Children are missing from the picture</i>	131
V. CONCLUDING REMARKS	132

I. INITIAL COMPREHENSION ON *SCHISTOSOMA* SPP. AND HIV INTERACTIONS

There is a need to better understand the epidemiology of HIV and *Schistosoma* spp. co-infections, the consequences of one disease on the public health interventions targeting the other, the confounders in the interaction, and the ways to alleviate the combined burden to improve quality of life. The 2013 Global Burden of Disease Study estimated that schistosomiasis alone causes 2.6 million Disability-Adjusted Life Years (DALYs) lost annually, while HIV infection alone causes 66.7 million DALYs¹. These numbers do not include the combined impact of co-infections. This thesis aimed at increasing the knowledge about HIV/*Schistosoma* spp. co-infections, as well as defining gaps in the past research methodology to improve future research and improve comparisons and advance accurateness of conclusions.

The studies described in this manuscript were conducted among the Tanzanian population of the Lake Zone, where regular HIV surveillance is conducted and where both *S. mansoni* and *S. haematobium* are present. *S. haematobium* and *S. mansoni* are thought to modify HIV epidemiology through both local and systemic modifications. *S. haematobium* eggs, as well as *S. mansoni* eggs to a lesser extent, can be found in the urogenital tract. They cause urogenital schistosomiasis, which is marked by inflammation, friability, and bleeding of the urinary and genital mucosa^{2, 3}. Men and women are affected differently by genital schistosomiasis as genital lesions due to eggs' sequestration and induced inflammation are less common in men than in women^{2, 4, 5}. In addition, sequestered eggs and their associated lesions in women are found in sites directly accessible during sexual contact³, which is not the case for men^{2, 4}. *Schistosoma* eggs are highly immunogenic and lead to recruitment of immune cells, including CD4+ T-cells (CD4 counts), that are preferential targets of HIV². In addition, *Schistosoma* spp. infection is typically thought to increase the Th2 immune response and lower the Th1 immune response, which causes increased levels of interleukines that may induce accelerated replication of HIV⁶.

Both HIV testing and *Schistosoma* spp. testing are important to take into account when comparing studies looking at the interaction between both infections. The Tanzanian national guidelines for HIV testing follow WHO recommendations. The standard procedure for diagnosis of HIV in our study population involves the use of rapid tests for antibody testing⁷ and since 2016, HIV RNA viral load quantification using PCR has been in place to evaluate response to ART⁸. Both CD4 counts and HIV RNA viral load change over the course of a natural HIV infection, and are predictors of the course of the HIV infection⁹⁻¹¹.

The current gold standard for diagnosis of active *Schistosoma* infection and detection of the species, as recommended by the WHO, is microscopy on urine or stool. It is less sensitive than other diagnostic strategies but has a near-perfect specificity and allows to differentiate between the infecting *Schistosoma* species if both urine and stool are provided. Schistosome antigen testing has been improved over the years to reach a high sensitivity and specificity for diagnosis of *Schistosoma* genus, although it does not allow distinction between *Schistosoma*

species¹². Circulating anodic antigen (CAA) and circulating cathodic antigen (CCA) can be detected either in the serum or in the urine of infected individuals, meaning the testing only requires one biological matrix to identify infection, and the level of these antigens is proportional to the intensity of infection¹². The CAA and CCA based tests have been optimized for use in the field and CAA testing has been improved to be able to use dried blood spot samples for testing¹³. Current PCR techniques detect active infection but are expensive and often do not distinguish between *Schistosoma* species¹².

There is a clear association between *Schistosoma* spp. and HIV in women in the literature¹⁴⁻¹⁸, and being infected with *Schistosoma* spp. increases the risk of HIV acquisition for women but not for men¹⁹⁻²². This is thought to be due to the difference in clinical urogenital schistosomiasis in men and women as mentioned above.

However there is still a lot unknown or poorly understood about HIV/*Schistosoma* spp. co-infections. Past studies have explored specific directions of the relationship between HIV and *Schistosoma* spp., looking separately on the one hand at the effect of *Schistosoma* spp. on HIV susceptibility and disease, and on the other hand at the effect of HIV on *Schistosoma* spp. infection. Most studies have looked at the effect of co-infections (in a cross-sectional way), while some have looked at the impact of *Schistosoma* spp. infection at time of HIV infection on HIV progression. There is still a lot of discrepancy in the literature regarding the role of *Schistosoma* spp. co-infection on HIV-RNA viral loads and CD4 counts, and regarding the role of HIV co-infection on *Schistosoma* spp. egg excretion. Based on schistosomiasis clinical differences between men and women, as well as differences in CD4 counts and HIV RNA viral load both between individuals and over the course of HIV infection, we would expect both sex and duration of HIV infection to be a main confounder in the relationship between HIV status and *Schistosoma* spp. infection.

The discussion will focus first on the conceptual framework presented in the introduction and the specific ways in which this thesis has strengthened our understanding of HIV/*Schistosoma* spp. co-infections. Then it will focus on the importance of taking into account HIV/*Schistosoma* spp. co-infections for prevention and diagnosis of both diseases, and finally it will indicate key limitations of most studies and recapitulate the questions that still remain to be answered.

II. REVISITING THE INITIAL CONCEPTUAL FRAMEWORK: WHAT GAPS DID WE FILL?

*1) Effects of *Schistosoma* spp. infection on HIV susceptibility and disease*

Studies had shown that co-infection with *Schistosoma* spp. increased HIV RNA viral load and viral load set point in humans^{19, 23-25}, as well as replication and reactivation of sHIV in macaques^{26, 27}. As a result, it had been hypothesized for years that co-infection with *Schistosoma* spp. would hasten progression to HIV/AIDS outcomes and would increase transmission^{28, 29}. Yet, to confirm these two assumptions, one needs longitudinal HIV/*Schistosoma* spp. co-infections studies. Ours were the first to try to answer these topics. The studies were built on the unique opportunity to have access to regular HIV testing results among a cohort of about 30,000 people over a period of 10 years and to be able to test the stored Dried Blood Spots (DBS) for the presence of *Schistosoma* spp. derived antigen indicating active infection at the time of DBS collection. The study results did not support the longstanding hypotheses but indicated the opposite (**Chapter 3 & 4**), explained in detail below.

A. *Schistosoma* spp. infection at time of HIV infection slows down AIDS progression

We found a highly significant protective effect of *Schistosoma* spp. infection against HIV outcomes (**Chapter 3**). This finding is unexpected if compared to studies showing increased HIV RNA viral loads during co-infection or shortly after HIV acquisition^{19, 23-25}. However it is in line with our study results described in **Chapter 5**. **Chapter 5** indeed showed that *Schistosoma*-infected individuals have lower HIV RNA viral loads for a given duration of HIV infection as compared to HIV-infected individuals without *Schistosoma* infections, while lower viral loads are usually synonym of better HIV/AIDS outcomes³⁰. It also coheres with the findings of multiple other studies that have reported increased CD4 counts and decreased HIV RNA viral loads in those with *Schistosoma* spp. infection, as compared to those without³¹⁻³⁵. Therefore, we posit that host immune responses to *Schistosoma* spp. could be protective against HIV/AIDS progression, particularly after a longer duration of HIV infection, and that this can affect the host's clinical outcome.

One possible mechanism of this protective effect could be via induction of Th1 HIV-specific immunity in *Schistosoma* spp. co-infected individuals³⁶⁻³⁹. In addition, *Schistosoma* spp. infection leads to increases in Th17 and regulatory T (Treg) cells, which plays a critical role in determining the speed of HIV/AIDS progression^{40, 41}. Lower Th17/Treg ratios have been associated with more advanced HIV infection⁴², while absolute increases in Treg numbers have been associated with decreased markers of immune activation^{42, 43}, potentially leading to better HIV outcomes. In contrast, higher absolute numbers of Th17 cells could prevent microbial translocation and thereby decrease immune hyperactivation, which has been associated with poorer HIV outcomes^{41, 42}. This, in combination with the previous immunological findings, suggests that there is not one way in which *Schistosoma* spp. infection influences HIV pathogenesis (and vice versa), but rather multiple pathways, that are

all balanced, and it is the ratios and balances and imbalances that will lead to an effect of one disease on the other⁴⁴⁻⁴⁷. The immunological pathways also likely change over time, making it essential to consider the length of infection with each disease and the duration of co-infection itself when trying to understand HIV and *Schistosoma* spp. co-infections.

B. *Schistosoma* spp. co-infection increases HIV transmission

While several studies have shown an increased risk of HIV acquisition of nearly 3 fold in women infected with *S. haematobium* or *S. mansoni*^{19, 20}, the risk of HIV transmission from men and women infected with *Schistosoma* spp. to healthy non-infected individuals is not as clear in our studies (**Chapter 4**). In our study population, *Schistosoma* spp. co-infection increased HIV transmission, although it was not statistically significant. The lack of significance was likely due to an overwhelming effect of the sex of the receiving partner on HIV transmission⁴⁸. Women are indeed more susceptible to HIV infection than males⁴⁸⁻⁴⁹. To remove this effect of sex of the receiving partner, further studies should investigate the effect of *Schistosoma* spp. in HIV positive male individuals and the associated risk for transmission to female sero-discordant partners. In addition, it is possible that the effect was small in our study population because most people were infected with *S. mansoni*^{13, 17, 18}, thus having lower prevalence of genital schistosomiasis and/or a lower density of egg-induced local changes that may facilitate HIV transmission, compared to infection with *S. haematobium*. The fact that *Schistosoma* spp. seems to be associated with higher risk of HIV acquisition and transmission (**Chapter 4**), but associated with better HIV/AIDS outcomes and lower HIV RNA viral loads (**Chapter 3 & 5**), suggests a dual (and likely opposite) effect of *Schistosoma* spp.: a local effect, associated with genital schistosomiasis, and systemic immunological changes. We found that *S. mansoni* infection leads to increased HIV transmission but only with a small effect (**Chapter 4**). We believe that the effect of *S. haematobium* on HIV transmission would have been larger, due to higher frequency and severity of urogenital schistosomiasis, and reinforces the idea that the effect of *Schistosoma* spp. co-infection on HIV transmission could be due to local genital inflammation rather than systemic immunological changes⁵⁰⁻⁵³.

C. *Schistosoma* spp. co-infection decreases HIV RNA viral load

Chapter 5 highlighted the need to account for the duration of HIV infection, through an approach taking into account CD4 counts at enrollment⁵⁴. This is a straightforward calculation, requiring minimal data, to account for duration of HIV infection that we would suggest to include in future study on HIV and *Schistosoma* spp. co-infection. The technique behind this method has been used in multiple studies and is drawing from several data sources⁵⁴⁻⁵⁹. Time infected with HIV is defined as the sum of the time between HIV acquisition and enrollment at a clinic and the time between enrollment at a clinic and enrollment in the study. The time infected with HIV before enrolling in a clinic is defined using the first CD4 counts reported at the clinic, which is used to approximate the time delay between HIV infection and enrollment as a function of normal CD4 decay per calendar year


in drug naïve individuals. The time between the first CD4 count reported at the clinic and the date of study testing is then added to this variable to obtain the duration of HIV infection.

In our study, the results derived from this method concurred with results issued from surveillance data alone and approximation of the start of HIV infection by the middle date between two discordant DBS (**Chapter 2**). Several studies on HIV alone suggest that the relationship between immunological responses and HIV RNA viral load or CD4 count does not remain constant throughout the entire course of HIV infection, which further complicates the understanding of the immunological interactions between HIV infection and *Schistosoma* spp. infection^{9-11, 60}.

Duration of *Schistosoma* spp. infection is more difficult to measure than for HIV, as natural clearance and reinfection happen regularly in the adult population⁶¹. Even when people report having recently taken praziquantel (PZQ), yet test positive for *Schistosoma* spp., one cannot always distinguish between reinfection, decreased responsiveness to PZQ, and poor adherence⁶²⁻⁶⁴. As PZQ is made more widely available to populations in need, its administration and impact must be evaluated but the lack of gold standard diagnosis test for *Schistosoma* spp. further complicates analyses⁶⁵. It can render studies that used microscopy and detected the presence of eggs in urine or stool difficult to compare to studies using, CAA or CCA and detecting worm derived antigens in blood or urine. Results are then also difficult to interpret. For example, how can a researcher measure the impact of HIV status on PZQ efficacy if he or she relies on microscopy since HIV status potentially impacts egg excretion?

The results from this thesis thus suggest two pathways through which *Schistosoma* spp. co-infections impact HIV epidemiology. The first pathway is a local one: genital mucosal friability and increased vascularity and bleeding, as well as increased seminal viral load lead to both increased transmission of HIV from an HIV/Schistosome co-infected individual to an HIV serodiscordant partner, and increased incidence of HIV in Schistosome infected women. The second pathway is a systemic one: Schistosomiasis leads to a modification in the Th17/Treg ratio, which in turn leads to decreased systemic viral load and better HIV/AIDS outcomes. We updated our conceptual framework of the mechanisms of the impact of *Schistosoma* spp. co-infections on HIV in **Figure 3**. The added mechanisms are shown in red.

Figure 1 - Updated conceptual framework of the epidemiology of HIV-Schistosome co-infections - Effect of Schistosoma spp. on HIV susceptibility and disease.



2) Effect of HIV on *Schistosoma* spp. infection


A. HIV co-infection reduces *Schistosoma* spp. egg excretion in men

Chapter 6 is the first large study to show an impact of HIV positivity on egg excretion. It demonstrates that the female to male ratio of the population studied was likely the main reason for conflicting results among previous studies^{33, 74, 77, 89-93}. HIV infection status does not significantly affect *Schistosoma* spp. egg excretion in women, with the sensitivity of microscopy in both HIV-infected people and women only approximating 40%. Because most of the previous large studies done on this subject included mostly or entirely women, a difference in egg excretion based on HIV status was not detected^{33, 77}. In contrast, the studies that included men, such as the Kenyan carwasher cohort, did report a difference in egg excretion⁷⁴. The impact of sex on *Schistosoma* spp. infections is intriguing, with differential effects in women and men also demonstrated in epidemiologic studies of HIV acquisition^{16, 17, 19, 94} and systemic immune responses to schistosome infection (Dupnik K, manuscript under review). Since the ratios of egg excretion to worm burden were lower in women infected with *S. mansoni*, the sex difference cannot be attributed to worm burden alone for this species. It is possible that CD4 counts could have been lower in men^{95, 96} and that this could have impacted egg excretion via an effect on T cells^{74, 75}. It is also possible that anatomical pelvic differences between men and women could lead to higher numbers of migrating parasite eggs trapped in female pelvic tissues than in males, or that worm fecundity could be affected by disparate immunological responses to *Schistosoma mansoni* worms in men versus women^{53, 97}.

The results of this thesis allowed us to explain part of the discrepancy in the results regarding the impact of HIV infection on *Schistosoma* pathophysiology: HIV infection leads to lower systemic CD4 counts, which in turn reduced *Schistosoma* spp. egg excretion in men but not in women. We updated our conceptual framework of the mechanisms of the impact of HIV co-infections on *Schistosoma* spp. in **Figure 4**. The added results are shown in red.

Given the multiple studies indicating that host sex is a main distorting factor in the interaction between HIV and *Schistosoma* infections, sex should be taken into account and stratified for in any future study.

Figure 2 - Updated conceptual framework of the epidemiology of HIV-Schistosome co-infections - Effect of HIV on Schistosoma spp. infection.



III. IMPLICATIONS FOR DIAGNOSIS AND PREVENTION

1) Diagnosis of *Schistosoma* spp.: microscopy testing is not recommended for women and HIV-infected individuals

Chapter 6 highlighted the need for new WHO recommendations regarding the use of microscopy for detection of *Schistosoma* spp., especially in women and HIV-infected individuals. This is particularly important in the context of large reductions in the burden of schistosomiasis through mass drug administration⁶⁴. As the prevalence of *Schistosoma* spp. infections decreases, the sensitivity of microscopy decreases too. One of the 2015-2030 United Nations Sustainable Development Goals is to eliminate schistosomiasis and other neglected tropical diseases altogether¹¹¹. Given the ability of the diagnostic tool detecting the worm derived CAA that can now detect as little as one worm pair, and the CAA half-life of two days after successful killing of the worm^{12, 112, 113}, this test is extremely well-suited to quantify cure rates and to estimate the impact of HIV on response to PZQ treatment or reinfection.

CAA testing also has the advantage of reflecting the worm burden better than microscopy¹². This allows detection of highly infected individuals, who might have differing immunity to *Schistosoma* compared to the rest of the population¹¹⁴. This in return allows for individual targeted treatment, and being able to detect highly infected individuals with unique immune responses might help better understand the immunological mechanisms at stake in *Schistosoma* spp. infections and co-infections.

In addition, Downs et al. came up with a proof-of-concept showing that DBS can be reliably used to quantify CAA: infection status can be determined even in DBS that had been stored for up to 8 years¹³. This opened new possibilities for other research studies on interactions between HIV and *Schistosoma* spp.. Of note, CAA testing is genus specific and additional testing is needed to indicate intestinal or urogenital infection^{65, Chapter 4}.

2) HIV prevention: targeting individuals present in *Schistosoma* spp.-endemic areas to contain the HIV epidemic

Our study results may add and improve current guidelines for HIV prevention. If *Schistosoma* spp. has a protective effect against poor HIV/AIDS outcome (**Chapter 3**), it does not mean that we should be stopping efforts to fight co-infections. Both diseases separately trigger millions of deaths and disabilities every year¹, and *Schistosoma* spp. infection is still a risk factor for HIV acquisition^{19, 20}, which is a main target of most HIV programs. Additional studies to determine whether PZQ treatment can prevent HIV acquisition should be prioritized, as PZQ treatment could be a safe, low-cost, acceptable way to prevent ongoing incident HIV infections in endemic regions. Current HIV/AIDS programs are aiming at improving care and ART availability for those who do get infected or were already infected in order to ultimately reduce the incidence of HIV¹¹⁵. **Chapter 2** shows that linkage to care is still poor in Tanzania and highlights the need for better integration from testing to enrollment into care. This chapter also calls for other ways to reduce the number of

people infected with HIV. Targeting individuals present in *Schistosoma* spp.-endemic areas, or those with known *Schistosoma* spp. infection, might help to curb the HIV epidemic. Both treating these individuals with PZQ and recommending more frequent HIV testing could lead to decreased seroconversion rates and better linkage to care. **Chapter 4** also suggests that future HIV/AIDS programs should focus their efforts on sero-discordant spouses.

Awareness regarding the relationship between HIV and *Schistosoma* spp. needs to be raised, not only among HIV/AIDS as well as *Schistosoma* spp. infection advocates, but clearly also among the general public. This could lead to an increase in the likelihood of HIV testing in populations exposed to both diseases such as fishermen, farmers, and those of lower socioeconomic status who do not have easy access to uncontaminated water sources. However, like with any disease campaign, public perceptions need to be managed appropriately and it will be essential to ensure that individuals with schistosomiasis do not become stigmatized¹¹⁶, to keep high uptake of routine anti-schistosome treatment and HIV testing.

IV. REMAINING QUESTIONS AND METHODOLOGY IMPROVEMENTS

1) More longitudinal studies are needed

At the epidemiological level, more longitudinal studies are needed to further clarify the impact of *Schistosoma* spp. infection on HIV RNA viral load set point, incidence, outcomes, and transmission. Longitudinal studies are often expensive, time-consuming, and ethically challenging¹¹⁷. A number of studies have used PZQ treatment to conclude on an effect of *Schistosoma* spp. infection on HIV pathogenesis^{23, 25, 31, 35, 79, 86, 105}. Yet one cannot take the effect of PZQ treatment as a proxy for being *Schistosoma* spp.-free. In itself, PZQ treatment highly modifies the immune system response by killing the worms and thus activates a Th2 immune response³¹. The impact of PZQ treatment in co-infected individuals should be a whole research question(s) in itself, as should be the impact of ART treatment in co-infected individuals. It is challenging to compare a population of ART naïve HIV positive individuals in regards to HIV RNA viral load to a population not entirely ART naïve or on ART¹¹⁸. With the increasing use of DBS in HIV care for HIV RNA viral load testing¹¹⁹, even in children, and the growing number of large sero-survey cohorts¹²⁰, CAA testing on DBS offers a cost-effective and convenient alternative to obtain human prospective data on the relationships between HIV and *Schistosoma* spp., with the potential to impact health policy and HIV prevention strategies throughout sub-Saharan Africa.

2) The immunological processes at stake are still not fully understood

At the immunological level, the impact of *Schistosoma* spp. infection on Th1 and Th2 immunity is still unclear in the context of HIV co-infections^{27, 31, 36-39, 85, 86}. As mentioned earlier, the discrepancies are likely coming from an interpretation based on absolute immunological responses rather than ratios and imbalances, as well as the lack of a time variable in most immunological studies done until now.

In addition, the differences in the human immune response to *S. haematobium* and *S. mansoni* are still poorly understood¹²¹. While the local differences in the genital tract have been well studied⁵¹⁻⁵³, it is still unknown whether there are some systemic differences in the pathogenesis of the interaction between HIV and *S. haematobium* or HIV and *S. mansoni*. As the majority of our study population was infected with *S. mansoni* it is possible that we would have seen different effects, especially regarding transmission, in an *S. haematobium* infected population.

3) Children are missing from the picture

Finally, despite Bustinduy et al. raising the attention on the lack of studies on HIV/*Schistosoma* spp. co-infections in children in 2014¹²², the literature on co-infections in children, or the impact of *Schistosoma* spp. infection during childhood on HIV infection as an adult, still only gathers one research study¹²³ and one literature review¹²². Given that the human immune response to schistosome infection changes with age and exposure, insight on co-infections in children will further add understanding to this complex issue⁴⁴.

V CONCLUDING REMARKS

The studies presented in this thesis have yielded further insight into the complex relationship between HIV and *Schistosoma* infection. They suggest a local interaction with urogenital schistosomiasis leading to increased incidence and transmission of HIV. They suggest as well a systemic interaction with *Schistosoma* spp. infection. The latter modifies immune responses to HIV, protecting against poor HIV outcomes. And HIV infection decreases CD4 counts, leading to decreased *Schistosoma* egg excretion.

The use of stored DBS from an HIV serosurvey cohort to test for *Schistosoma* spp. offered a unique opportunity to investigate the questions of outcomes and transmission in the context of HIV/*Schistosoma* spp. co-infections, by overcoming logistical and ethical difficulties associated with prospective cohort studies. Our work also highlighted the added benefit of using CAA as a diagnostic test for *Schistosoma* spp. Finally it offered new ways to include duration of HIV infection using CD4 counts in future research and suggested that *Schistosoma* spp. infection lowers HIV RNA viral load in ART naïve individuals.

Future research should focus on longitudinal studies and immunological studies, taking into account duration of infection, sex of the host, and infecting species of *Schistosoma*.

KEY FINDINGS

- People with *Schistosoma* spp. infection at the time of HIV-seroconversion develop adverse HIV outcomes more slowly than those without.
- Current infection with *Schistosoma* spp. is associated with significantly lower HIV viral loads after adjusting for time infected with HIV in ART naïve populations.
- Both women and HIV-infected individuals are significantly less likely to excrete *Schistosoma* spp. eggs when infected, even after controlling for a given worm antigen level.
- *Schistosoma* spp. infection in the transmitting partner has only a small effect on transmission of HIV due to the major effect of the sex of the receiving partner in HIV transmission
- Host sex and duration of HIV infection are likely main confounders, leading to the discrepancy in results in previous studies.
- More longitudinal studies are needed to further clarify the impact of *Schistosoma* spp. infection on HIV RNA viral load set point, incidence, outcomes, and transmission.
- Our Tanzanian study population demonstrates some moderate successes in linkage to care, with 80% of HIV-infected people knowing their HIV status and 62% of these being on ART.

REFERENCES

1. Kassebaum NJ, Arora M, Barber RM, Bhutta ZA, Brown J, Carter A, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016; 388(10053):1603-1658.
2. Stecher CW, Kallestrup P, Kjetland EF, Vennervald B, Petersen E. Considering treatment of male genital schistosomiasis as a tool for future HIV prevention: a systematic review. *Int J Public Health*. 2015;60(7):839-48. doi:10.1007/s00038-015-0714-7.
3. Kjetland EF, Leutscher PDC, Ndhlovu PD. A review of female genital schistosomiasis. *Trends Parasitol*. 2012;28(2):58-65. doi:10.1016/j.pt.2011.10.008.
4. Gelfand M, Ross CM, Blair DM, Castle WM, Weber MC. Schistosomiasis of the male pelvic organs. Severity of infection as determined by digestion of tissue and histologic methods in 300 cadavers. *Am J Trop Med Hyg*. 1970;19(5):779-84.
5. Gelfand M, Ross MD, Blair DM, Weber MC. Distribution and extent of schistosomiasis in female pelvic organs, with special reference to the genital tract, as determined at autopsy. *Am J Trop Med Hyg*. 1971 Nov; 20(6):846-9.
6. Leutscher PD, Pedersen M, Raharisolo C, Jensen JS, Hoffmann S, Lisse I, et al (2005) Increased prevalence of leukocytes and elevated cytokine levels in semen from *Schistosoma haematobium*-infected individuals. *J Infect Dis*. 2005;191(10):1639–1647. doi:10.1086/429334.
7. The United Republic of Tanzania. Ministry of Health. National guidelines for the clinical management of HIV and AIDS. National AIDS Control Programme 2nd ed. 2005 Apr.
8. The United Republic of Tanzania. Ministry of Health and Social Welfare. National guidelines for the management of HIV and AIDS. National AIDS Control Programme 5th ed. 2015 May.
9. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. *AIDS*. 2008;22(16): 2179.
- 10.- Patrikar S, Basannar DR, Bhatti VK, Kotwal A, Gupta RM, Grewal RS. Rate of decline in CD4 count in HIV patients not on antiretroviral therapy. *Med J Armed Forces India*. 2014; 70(2): 134-138.
11. Arnaout RA, Lloyd AL, O'Brien TR, Goedert JJ, Leonard JM, Nowak MA. A simple relationship between viral load and survival time in HIV-1 infection. *Proc Natl Acad Sci*. 1999;96(20): 11549-11553.
12. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. *Clin Microbiol Inf*. 2015; 21(6), 529-542.
13. Downs JA, Corstjens PLAM, Mngara J, Lutonja P, Isingo R, Urassa M, et al. Correlation of Serum and Dried Blood Spot Results for Quantitation of *Schistosoma* Circulating Anodic Antigen: a Proof of Principle. *Acta Trop*. 2015;150:59-63. doi:10.1016/j.actatropica.2015.06.026.
14. Ndeffo Mbah ML, Poolman EM, Drain PK, Coffee MP, Werf MJ, Galvani AP. HIV and *Schistosoma haematobium* prevalences correlate in sub-Saharan Africa. *Trop Med Int Health*. 2013; 18(10), 1174-1179.
15. Brodish PH, Singh K. Association Between *Schistosoma haematobium* Exposure and Human Immunodeficiency Virus Infection Among Females in Mozambique. *Am J Trop Med Hyg*. 2016;94: 1040-4.
16. de Lima e Costa MF, Proietti FA, Paulino UH, Antunes CM, Guimaraes MD, Rocha RS, et al. Absence of cross-reactivity between *Schistosoma mansoni* infection and human immunodeficiency virus (HIV). *Trans R Soc Trop Med Hyg*. 1998;82: 262.
17. Downs JA, de Dood CJ, Dee HE, McGeehan M, Khan H, Marenga A, et al. Schistosomiasis and Human Immunodeficiency Virus in Men in Tanzania. *Am J Trop Med Hyg*. 2017;96: 856-862.
18. Downs JA, van Dam GJ, Chagalucha JM, Corstjens PL, Peck RN, de Dood CJ, et al. Association of Schistosomiasis and HIV infection in Tanzania. *Am J Trop Med Hyg*. 2012;87: 868-73.
19. Downs JA, Dupnik KM, van Dam GJ, Urassa M, Lutonja P, Kornelis D, et al. Effects of schistosomiasis on susceptibility to HIV-1 infection and HIV-1 viral load at HIV-1 seroconversion: A nested case-control study. *PLoS Negl Trop Dis*. 2017; 11(9), e0005968.
20. Ndeffo Mbah ML, Gilbert JA, Galvani AP. Evaluating the potential impact of mass praziquantel administration for HIV prevention in *Schistosoma haematobium* high-risk communities. *Epidemics*. 2014;7: 22-7.

21. Ndeffo Mbah ML, Kjetland EF, Atkins KE, Poolman EM, Orenstein EW, Meyers LA, et al. Cost-effectiveness of a community-based intervention for reducing the transmission of *Schistosoma haematobium* and HIV in Africa. *Proc Natl Acad Sci USA*. 2013;110: 7952-7.
22. Mushayabasa S, Bhunu CP. Modeling schistosomiasis and HIV/AIDS codynamics. *Comput Math Methods Med*. 2011;2011: 846174.
23. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, Mudenge B, van Dam GJ, et al. Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. *J Infect Dis*. 2005;192: 1956-61.
24. Sangare LR, Herrin BR, John-Stewart G, Walson JL. Species-specific treatment effects of helminth/HIV-1 co-infection: a systematic review and meta-analysis. *Parasitology*. 2011;138: 1546-58.
25. Midzi N, Mduluza T, Mudenge B, Foldager L, Leutscher PDC. Decrease in Seminal HIV-1 RNA Load After Praziquantel Treatment of Urogenital Schistosomiasis Coinfection in HIV-Positive Men-An Observational Study. *Open Forum Infect Dis*. 2017;4: ofx199.
26. Chenine AL, Shai-Kobiler E, Steele LN, Ong H, Augostini P, Song R, et al. Acute *Schistosoma mansoni* infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. *PLoS Negl Trop Dis*. 2008;2: e265.
27. Chenine AL, Buckley KA, Li PL, Rasmussen RA, Ong H, Jiang S, et al. *Schistosoma mansoni* infection promotes SHIV clade C replication in rhesus macaques. *AIDS*. 2005;19: 1793-7.
28. Feldmeier H, Krantz I, Poggensee G. Female genital schistosomiasis: a neglected risk factor for the transmission of HIV? *Trans R Soc Trop Med Hyg*. 1995;89: 237.
29. Secor WE. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. *Curr Opin HIV AIDS*. 2012;7: 254-9.
30. Mellors JW, Rinaldo Jr CR, Gupta P, White RM. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*. 1996; 272(5265), 1167.
31. Brown M, Mawa PA, Joseph S, Bukusuba J, Watera C, Whitworth JA, et al. Treatment of *Schistosoma mansoni* infection increases helminth-specific type 2 cytokine responses and HIV-1 loads in coinfecting Ugandan adults. *J Infect Dis*. 2005;191: 1648-57.
32. Elliott AM, Mawa PA, Joseph S, Namujju PB, Kizza M, Nakiyingi JS, et al. Associations between helminth infection and CD4+ T cell count, viral load and cytokine responses in HIV-1-infected Ugandan adults. *Trans R Soc Trop Med Hyg*. 2003;97: 103-8.
33. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Erikstrup C, et al. Schistosomiasis and HIV-1 infection in rural Zimbabwe: implications of coinfection for excretion of eggs. *J Infect Dis*. 2005; 191: 1311-20.
34. Prodger JL, Ssemaganda A, Ssetaala A, Kitandwe PK, Muyanja E, Mpendo J, et al. *Schistosoma mansoni* Infection in Ugandan Men Is Associated with Increased Abundance and Function of HIV Target Cells in Blood, but Not the Foreskin: A Cross-sectional Study. *PLoS Negl Trop Dis*. 2015;9: e0004067.
35. Lawn SD, Karanja DM, Mwinzia P, Andove J, Colley DG, Folks TM, et al. The effect of treatment of schistosomiasis on blood plasma HIV-1 RNA concentration in coinfecting individuals. *AIDS*. 2000;14: 2437-43.
36. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of *Schistosoma mansoni* Infection on Innate and HIV-1-Specific T-Cell Immune Responses in HIV-1-Infected Ugandan Fisher Folk. *AIDS Res Hum Retroviruses*. 2016;32: 668-75.
37. Bui CT, Shollenberger LM, Paterson Y, Harn DA. *Schistosoma mansoni* soluble egg antigens enhance *Listeria monocytogenes* vector HIV-1 vaccine induction of cytotoxic T cells. *Clin Vaccine Immunol*. 2014;21: 1232-9.
38. Bui CT, Shollenberger LM, Paterson Y, Harn DA. *Schistosoma mansoni* soluble egg antigens enhance T cell responses to a newly identified HIV-1 Gag H-2b epitope. *Clin Vaccine Immunol*. 2015;22: 193-9.
39. McElroy MD, Elrefaei M, Jones N, Ssali F, Mugenyi P, Barugahare B, et al. Coinfection with *Schistosoma mansoni* is associated with decreased HIV-specific cytotoxicity and increased IL-10 production. *J Immunol*. 2005;174: 5119-23.
40. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. *Blood*. 2013; 121(1), 29-37.

41. Valverde-Villegas JM, Matte MCC, Medeiros RMD, Chies, JAB. New insights about Treg and Th17 cells in HIV infection and disease progression. *J Immunol Res*. 2015; 2015:647916.
42. Falivene J, Ghiglione Y, Laufer N, Socías ME, Holgado MP, Ruiz MJ, et al. Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8⁺ T-cell responses and disease progression. *Sci Rep*. 2015; 5, 11511.
43. Schulze Zur Wiesch J, Thomssen A, Hartjen P, Tóth I, Lehmann C, Meyer-Olson D, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3⁺ T regulatory cells correlates with progressive disease. *J Virol*. 2011; 85(3):1287-97.
44. Colley DG, Secor WE. Immunology of human schistosomiasis. *Parasite Immunol*. 2014;36(8):347-357. doi:10.1111/pim.12087.
45. Jenkins SJ, Hewitson JP, Jenkins GR, Mountford AP. Modulation of the host's immune response by schistosome larvae. *Parasite immunol*. 2005;27(10-11):385-393. doi:10.1111/j.1365-3024.2005.00789.x.
46. Vyas SP, Goswami R. Striking the right immunological balance prevents progression of tuberculosis. *Inflamm Res*. 2017;6: 1031. <https://doi.org/10.1007/s00011-017-1081-z>.
47. Deroost K, Pham TT, Opendakker G, Van den Steen PE. The immunological balance between host and parasite in malaria. *FEMS Microbiol Rev*. 2016;40(2):208-257.
48. Griesbeck M, Scully E, Altfeld M. Sex and gender differences in HIV-1 infection. *Clin Sci*. 2016; 130(16): 1435-1451.
49. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet*. 2001;357(9263):1149-53. doi:10.1016/S0140-6736(00)04331-2.
50. Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, Downs JA. Examining the relationship between urogenital schistosomiasis and HIV infection. *PLoS Negl Trop Dis*. 2011;5: e1396.
51. Feldmeier H, Daccal RC, Martins MJ, Soares V, Martins R. Genital manifestations of schistosomiasis mansoni in women: important but neglected. *Mem. Inst. Oswaldo Cruz*. 1998; 93:127-133.
52. Gelfand M, Ross WF. II. The distribution of schistosome ova in the genito-urinary tract in subjects of bilharziasis. *Trans Roy Soc Trop Med Hyg*. 1953; 47(3): 218-20.
53. Cheever AW, Kamel IA, Elwi AM, Mosimann, JE, Danner R. Schistosoma Mansonii and S. Haematobium Infections in Egypt. *Am J Trop Med Hyg*. 1977; 26(4): 702-716.
54. Forbi JC, Forbi TD, Agwale SM. Estimating the time period between infection and diagnosis based on CD4⁺ counts at first diagnosis among HIV-1 antiretroviral naïve patients in Nigeria. *J Infect Dev Ctries*. 2010; 4(10):662-667.
55. Vanhems P, Lambert J, Guerra M, Hirschel B, Allard R. Association between the rate of CD4⁺ T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study. *J Infect Dis*. 1999;180:1803-8. doi: 10.1086/315110.
56. Taffé P, May M, Study SHC. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. *Stat Med*. 2008;27:4835-53. doi: 10.1002/sim.3294.
57. Birrell PJ, Gill ON, Delpech VC, Brown AE, Desai S, Chadborn TR, et al. HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study. *Lancet Infect Dis*. 2013 Apr;13(4):313-8.
58. Van Sighem A, Nakagawa F, De Angelis D, Quinten C, Bezemer D, de Coul EO, et al. Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. *Epidemiology*. 2015; 26(5):653-660. doi:10.1097/EDE.0000000000000324.
59. Wong NS, Wong KH, Lee MP, Tsang OTY, Chan DPC, Lee SS. Estimation of the Undiagnosed Intervals of HIV-Infected Individuals by a Modified Back-Calculation Method for Reconstructing the Epidemic Curves. *PLoS One*. 2016;11(7):e0159021. doi:10.1371/journal.pone.0159021.
60. Martinson NA, Gupta N, Msandiwa R, Moulton LH, Barnes GL, Ram M, et al. CD4 and viral load dynamics in antiretroviral-naïve HIV-infected adults from Soweto, South Africa: a prospective cohort. *PLoS One*. 2014;9(5): e96369.
61. Mbanefo EC, Huy NT, Wadagni AA, Eneanya CI, Nwaorgu O, Hirayama, K. Host determinants of reinfection with schistosomes in humans: a systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2014;8(9):e3164.

62. Inobaya MT, Olveda RM, Chau TN, Olveda DU, Ross AG. Prevention and control of schistosomiasis: a current perspective. *Res Rep Trop Med*. 2014;2014(5):65-75. doi:10.2147/RRTM.S44274.
63. Pinot de Moira A, Fulford AJC, Kabatereine NB, Ouma JH, Booth M, Dunne DW. Analysis of Complex Patterns of Human Exposure and Immunity to Schistosomiasis mansoni: The Influence of Age, Sex, Ethnicity and IgE. *PLoS Negl Trop Dis*. 2010;4(9):e820. doi:10.1371/journal.pntd.0000820.
64. Ross AG, Chau TN, Inobaya MT, Olveda RM, Li Y, Harn DA. A new global strategy for the elimination of schistosomiasis. *Int J Infect Dis*. 2017 Jan;54:130-137. doi: 10.1016/j.ijid.2016.09.023.
65. Weerakoon KGAD, Gobert GN, Cai P, McManus DP. Advances in the Diagnosis of Human Schistosomiasis. *Clin Microbiol Rev*. 2015;28(4):939-967. doi:10.1128/CMR.00137-14.
66. Gordon MA, Zijlstra EE, Naus CW, Visser LG, Molyneux ME, van Lieshout L. Schistosomiasis does not contribute to death or recurrence of nontyphoid Salmonella bacteremia in human immunodeficiency virus-infected Malawian adults. *Clin Infect Dis*. 2003;37: e177-9.
67. Brown M, Miiro G, Nkurunziza P, Watera C, Quigley MA, Dunne DW, et al. Schistosoma mansoni, nematode infections, and progression to active tuberculosis among HIV-1-infected Ugandans. *Am J Trop Med Hyg*. 2006;74: 819-25.
68. Kjetland EF, Hegertun IE, Baay MF, Onsrud M, Ndhlovu PD, Taylor M. Genital schistosomiasis and its unacknowledged role on HIV transmission in the STD intervention studies. *Int J STD AIDS*. 2014;25: 705-15.
69. Everett DB, Baisely KJ, McNerney R, Hambleton I, Chirwa T, Ross DA, et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. *J Clin Microbiol*. 2010;48: 1570-7.
70. Efraim L, Peck RN, Kalluvya SE, Kabangila R, Mazigo HD, Mpondo B, et al. Schistosomiasis and impaired response to antiretroviral therapy among HIV-infected patients in Tanzania. *J Acquir Immune Defic Syndr*. 2013; 62:e153–6. doi: 10.1097/QAI.0b013e318282a1a4.
71. Downs JA, Msango L, Kalluvya SE, Kidenya BR, Kabangila R, Peck RN. Renal dysfunction and schistosomiasis among HIV-infected patients starting antiretroviral therapy in Mwanza, Tanzania. *AIDS*. 2015;29: 2532-3.
72. Marti AI, Colombe S, Masikini PJ, Kalluvya SE, Smart LR, Wajanga BM, et al. Increased hepatotoxicity among HIV-infected adults co-infected with Schistosoma mansoni in Tanzania: A cross-sectional study. *PLoS Negl Trop Dis*. 2017;11: e0005867.
73. Ndeffo Mbah ML, Poolman EM, Atkins KE, Orenstein EW, Meyers LA, Townsend JP, et al. 2013. Potential Cost-Effectiveness of Schistosomiasis Treatment for Reducing HIV Transmission in Africa – The Case of Zimbabwean Women. *PLoS Negl Trop Dis*. 2013;7(8):e2346. doi:10.1371/journal.pntd.0002346.
74. Karanja DM, Colley DG, Nahlen BL, Ouma JH, Secor WE. Studies on schistosomiasis in western Kenya: I. Evidence for immune-facilitated excretion of schistosome eggs from patients with Schistosoma mansoni and human immunodeficiency virus coinfections. *Am J Trop Med Hyg*. 1997;56: 515-21.
75. Muok EM, Simiyu EW, Ochola EA, Ng'ang'a ZW, Secor WE, Karanja DM, et al. Association between CD4+ T-lymphocyte counts and fecal excretion of Schistosoma mansoni eggs in patients coinfecting with S. mansoni and human immunodeficiency virus before and after initiation of antiretroviral therapy. *Am J Trop Med Hyg*. 2013;89: 42-5.
76. Smith C, Smith H, Seaton RA, Fox R. Seroprevalence of schistosomiasis in African patients infected with HIV. *HIV Med*. 2008;9: 436-9.
77. Kleppa E, Klinge KF, Galaphaththi-Arachchige HN, Holmen SD, Lillebo K, Onsrud M, et al. Schistosoma haematobium infection and CD4+ T-cell levels: a cross-sectional study of young South African women. *PLoS One*. 2015;10: e0119326.
78. Brown M, Kizza M, Watera C, Quigley MA, Rowland S, Hughes P, et al. Helminth infection is not associated with faster progression of HIV disease in coinfecting adults in Uganda. *J Infect Dis*. 2004;190: 1869-79.
79. Walson J, Singa B, Sangare L, Naulikha J, Piper B, Richardson B, et al. Empiric deworming to delay HIV disease progression in adults with HIV who are ineligible for initiation of antiretroviral treatment (the HEAT study): a multi-site, randomised trial. *Lancet Infect Dis*. 2012;12: 925-32.

80. Noormahomed EV, Nhacupe N, Mascaro-Lazcano C, Mauaie MN, Buene T, Funzamo CA, et al. A cross-sectional serological study of cysticercosis, schistosomiasis, toxocariasis and echinococcosis in HIV-1 infected people in Beira, Mozambique. *PLoS Negl Trop Dis*. 2014;8: e3121.
81. Mwinzi PN, Karanja DM, Kareko I, Magak PW, Orago AS, Colley DG, et al. Short report: Evaluation of hepatic fibrosis in persons co-infected with *Schistosoma mansoni* and human immunodeficiency virus 1. *Am J Trop Med Hyg*. 2004;71: 783-6.
82. Sadlier CM, Brown A, Lambert JS, Sheehan G, Mallon PW. Seroprevalence of Schistosomiasis and Strongyloides infection in HIV-infected patients from endemic areas attending a European infectious diseases clinic. *AIDS Res Ther*. 2013;10: 23.
83. Jourdan PM, Holmen SD, Gundersen SG, Roald B, Kjetland EF. HIV target cells in *Schistosoma haematobium*-infected female genital mucosa. *Am J Trop Med Hyg*. 2011;85: 1060-4.
84. Ssetaala A, Nakiyingi-Miiro J, Asiki G, Kyakuwa N, Mpendo J, Van Dam GJ, et al. *Schistosoma mansoni* and HIV acquisition in fishing communities of Lake Victoria, Uganda: a nested case-control study. *Trop Med Int Health*. 2015;20: 1190-1195.
85. Ayash-Rashkovsky M, Chenine AL, Steele LN, Lee SJ, Song R, Ong H, et al. Coinfection with *Schistosoma mansoni* reactivates viremia in rhesus macaques with chronic simian-human immunodeficiency virus clade C infection. *Infect Immun*. 2007;75: 1751-6.
86. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, van Dam GJ, Deelder AM, et al. Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis. *Am J Trop Med Hyg*. 2008; 79: 331-7.
87. Secor WE, Shah A, Mwinzi PM, Ndenga BA, Watta CO, Karanja DM. Increased density of human immunodeficiency virus type 1 coreceptors CCR5 and CXCR4 on the surfaces of CD4(+) T cells and monocytes of patients with *Schistosoma mansoni* infection. *Infect Immun*. 2003;71: 6668-71.
88. Siddappa NB, Hemashettar G, Shanmuganathan V, Semanya AA, Sweeney ED, Paul KS, et al. *Schistosoma mansoni* enhances host susceptibility to mucosal but not intravenous challenge by R5 Clade C SHIV. *PLoS Negl Trop Dis*. 2011;5: e1270.
89. Mazigo HD, Dunne DW, Wilson S, Kinung'hi SM, Pinot de Moira A, Jones FM, et al. Co-infection with *Schistosoma mansoni* and Human Immunodeficiency Virus-1 (HIV-1) among residents of fishing villages of north-western Tanzania. *Parasit Vectors*. 2014;7: 587.
90. Olusegun AF, Ehis OC, Richard O. Proportion of Urinary Schistosomiasis among HIV-Infected Subjects in Benin City, Nigeria. *Oman Med J*. 2011;26: 175-7.
91. Sanya RE, Muhangi L, Nampijja M, Nannozi V, Nakawungu PK, Abayo E, et al. *Schistosoma mansoni* and HIV infection in a Ugandan population with high HIV and helminth prevalence. *Trop Med Int Health*. 2015;20: 1201-1208.
92. Fontanet AL, Woldemichael T, Sahlu T, van Dam GJ, Messele T, Rinke de Wit T, et al. Epidemiology of HIV and *Schistosoma mansoni* infections among sugar-estate residents in Ethiopia. *Ann Trop Med Parasitol*. 2000;94: 145-55.
93. Mwanakasale V, Vounatsou P, Sukwa TY, Ziba M, Ernest A, Tanner M. Interactions between *Schistosoma haematobium* and human immunodeficiency virus type 1: the effects of coinfection on treatment outcomes in rural Zambia. *Am J Trop Med Hyg*. 2003;69: 420-8.
94. Biggar MJ, Melbye M, Sarin PS, Kestens L, Sarin PS, Bodner AJ, et al. ELISA HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Africans. *Lancet*. 1985;2(8454):520-523.
95. Delmas M-C, Jadand C, De Vincenzi I, Deveau C, Persoz A, Sobel A, et al. Gender differences in CD4+ cell counts persist after HIV-1 infection. *AIDS*. 1997;11: 1071-73.
96. Loupa CV, Rodriguez B, McComsey G, Gripshover B, Salata RA, Valdez H, et al. Gender differences in human immunodeficiency virus (HIV) RNA and CD4 cell counts among new entrants to HIV care. *Clin Microbiol Infect*. 2006;12(4):389-91.
97. Wilson S, Jones FM, van Dam GJ, Corstjens PL, Riveau G, Fitzsimmons CM, et al. Human *Schistosoma haematobium* antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigens. *J Infect Dis*. 2014;210(12): 2009-2016.

98. Khalife J, Grzych JM, Pierce R, Ameisen JC, Schacht AM, Gras-Masse H, et al. Immunological crossreactivity between the human immunodeficiency virus type 1 virion infectivity factor and a 170-kD surface antigen of *Schistosoma mansoni*. *J Exp Med*. 1990;172: 1001-4.
99. Chacin de Bonilla L. *Schistosoma mansoni* and human immunodeficiency virus: new research avenues. *Invest Clin*. 1991;32: 1-2.
100. Khalife J, Pierce RJ, Godin C, Capron A. Molecular characterization of two *Schistosoma mansoni* proteins sharing common motifs with the vif protein of HIV-1. *Parasitology*. 1994;108 (Pt 5): 533-42.
101. Suttiprapa S, Rinaldi G, Tsai IJ, Mann VH, Dubrovsky L, Yan HB. HIV-1 Integrates Widely throughout the Genome of the Human Blood Fluke *Schistosoma mansoni*. *PLoS Pathog*. 2016;12: e1005931.
102. Mello MA, Mascarenhas RE, Ferraro GA, Harn D, Galvao-Castro M, Bou-Habib DC. Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of *Schistosoma mansoni*. *Med Microbiol Immunol*. 2005;194: 61-5.
103. Shollenberger LM, Bui CT, Paterson Y, Nyhoff L, Harn DA. HIV-1 vaccine-specific responses induced by *Listeria* vector vaccines are maintained in mice subsequently infected with a model helminth parasite, *Schistosoma mansoni*. *Vaccine*. 2013;31: 5651-8.
104. Karanja DM, Hightower AW, Colley DG, Mwinzi PN, Galil K, Andove J, et al. Resistance to reinfection with *Schistosoma mansoni* in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. *Lancet*. 2002;360: 592-6.
105. Joseph S, Jones FM, Laidlaw ME, Mohamed G, Mawa PA, Namujju PB, et al. Impairment of the *Schistosoma mansoni*-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection. *J Infect Dis*. 2004;190: 613-8.
106. Mwinzi PN, Karanja DM, Colley DG, Orago AS, Secor WE. Cellular immune responses of schistosomiasis patients are altered by human immunodeficiency virus type 1 coinfection. *J Infect Dis*. 2001;184: 488-96.
107. Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, et al. Correlation between eosinophils and protection against reinfection with *Schistosoma mansoni* and the effect of human immunodeficiency virus type 1 coinfection in humans. *Infect Immun*. 2006;74: 2169-76.
108. Mazigo HD, Dunne DW, Kinung'hi SM, Nuwaha F. Praziquantel efficacy against *Schistosoma mansoni* among HIV-1 infected and uninfected adults living in fishing villages along Lake Victoria, Northwest Tanzania. *Infect Dis Poverty*. 2014;3: 47.
109. Karanja DM, Boyer AE, Strand M, Colley DG, Nahlen BL, Ouma JH, et al. Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfecting with human immunodeficiency virus-1. *Am J Trop Med Hyg*. 1998;59: 307-11.
110. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Gerstoft J, et al. Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection. *Clin Infect Dis*. 2006;42: 1781-9.
111. Hotez PJ, Herricks JR. Helminth Elimination in the Pursuit of Sustainable Development Goals: A "Worm Index" for Human Development. Lustigman S, ed. *PLoS Negl Trop Dis*. 2015;9(4):e0003618. doi:10.1371/journal.pntd.0003618.
112. de Jonge N, De Caluwé P, Hilberath GW, Krijger FW, Polderman AM, Deelder AM. Circulating anodic antigen levels in serum before and after chemotherapy with praziquantel in schistosomiasis mansoni. *Trans R Soc Trop Med Hyg*. 1989;83(3):368-72.
113. van Lieshout L, de Jonge N, Bassily S, Mansour MM, Deelder AM. Assessment of cure in schistosomiasis patients after chemotherapy with praziquantel by quantitation of circulating anodic antigen (CAA) in urine. *Am J Trop Med Hyg*. 1991 Mar;44(3):323-8.
114. Guyatt HL, Smith T, Gryseels B, Lengeler C, Mshinda H, Siziya S, et al. Aggregation in schistosomiasis: comparison of the relationships between prevalence and intensity in different endemic areas. *Parasitology*. 1994;109(1), 45-55.
115. The United Republic of Tanzania. National AIDS Control Program. National HIV AIDS Priority Area. Available at: <http://www.nacp.go.tz/site/about/national-hiv-aids-priority-areas>.
116. Birgitte Bruun B, Aagaard-Hansen J. The social context of schistosomiasis and its control: an introduction and annotated bibliography. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases, 2008.

117. Carrel M, Rennie S. Demographic and health surveillance: longitudinal ethical considerations. *Bulletin of the World Health Organization*. 2008;86(8):612-616. doi:10.2471/BLT.08.051037.
118. Kestens L, Seddiki N, Bohjanen PR. Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. *Cur Opin HIV AIDS*. 2008;3(4):419-424. doi:10.1097/COH.0b013e328302ebbb.
119. Phillips AN, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, et al. Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile. *Open Forum Infect Dis*. 2016;3(3):ofw161. doi:10.1093/ofid/ofw161.
120. Reniers G, Wamukoya M, Urassa M, Nyaguara A, Nakiyingi-Miiró J, Lutalo T, et al. Data Resource Profile: Network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA Network). *Int J Epidemiol*. 2016 Feb;45(1):83-93.
121. Meurs L, Mbow M, Boon N, Vereecken K, Amoah AS, Labuda LA, et al. Cytokine Responses to *Schistosoma mansoni* and *Schistosoma haematobium* in Relation to Infection in a Co-endemic Focus in Northern Senegal. *PLoS Negl Trop Dis*. 2014;8(8):e3080. doi:10.1371/journal.pntd.0003080.
122. Bustinduy A, King C, Scott J, Appleton S, Sousa-Figueiredo JC, Betson M, et al. HIV and schistosomiasis co-infection in African children. *Lancet Infect Dis*. 2014;14: 640-9.
123. Kayange NM, Smart LR, Downs JA, Maskini M, Fitzgerald DW, Peck RN. The influence of HIV and schistosomiasis on renal function: a cross-sectional study among children at a hospital in Tanzania. *PLoS Negl Trop Dis*. 2015;9: e0003472.